Best Growth Hormone Peptides (2026): GHRPs, GHRHs & Secretagogues Ranked

Growth hormone (GH) secretagogues are the most popular category of peptides used in anti-aging, performance, and body composition optimization. They work by stimulating the pituitary gland to release more of the body's own growth hormone rather than injecting exogenous GH directly. This preserves pulsatile release patterns, avoids the feedback shutdown that exogenous GH produces, and generally carries a milder side effect profile.

But the category contains compounds with meaningfully different pharmacology, evidence quality, side effect profiles, and practical characteristics. This guide ranks them based on the intersection of efficacy evidence, side effect profiles, and clinical applicability as of 2026.

Understanding the Two Pathways

Before ranking individual compounds, it is essential to understand the two primary mechanisms through which GH secretagogues work. This distinction determines how the peptides are used, combined, and evaluated.

The GHRH Pathway

Growth hormone-releasing hormone (GHRH) is produced by the hypothalamus and acts on GHRH receptors (GHRHR) on pituitary somatotrophs. GHRH binding opens ion channels, increases intracellular cAMP, and directly stimulates GH synthesis and secretion. Natural GHRH has a very short half-life (approximately 7 minutes) due to rapid degradation by dipeptidyl peptidase-IV (DPP-IV).

GHRH analogs (Sermorelin, CJC-1295, Tesamorelin) mimic or extend this signal. They amplify the amplitude of GH pulses but are subject to somatostatin inhibition — meaning they work best when somatostatin tone is low (during natural GH release windows like deep sleep).

The GHRP/Ghrelin Pathway

Growth hormone-releasing peptides (GHRPs) act on the growth hormone secretagogue receptor (GHS-R1a), also known as the ghrelin receptor. This pathway is distinct from GHRH signaling and operates through phospholipase C and intracellular calcium mobilization. Importantly, GHRPs partially suppress somatostatin, which means they can initiate GH pulses even when somatostatin tone is high.

GHRPs (Ipamorelin, GHRP-2, GHRP-6, Hexarelin) function as GH pulse initiators, while GHRH analogs function as pulse amplifiers. This complementary pharmacology is the rationale for combining one of each.

Why Combining GHRP + GHRH Is Synergistic

The combination of a GHRP and a GHRH analog produces a synergistic GH release that is greater than the sum of either alone. The GHRP suppresses somatostatin and initiates the pulse, while the GHRH analog amplifies the pulse amplitude. Published data shows that the combination can produce GH spikes 3 to 10 times higher than either peptide alone. The CJC-1295/Ipamorelin combination is the most commonly used pairing for this reason.

The Rankings

Tier 1: Best Overall Profile

1. Ipamorelin

Class: GHRP (ghrelin receptor agonist)

Evidence level: Phase I/II human data, multiple pharmacokinetic studies

Ipamorelin occupies the top position because of its selectivity. Unlike GHRP-2 and GHRP-6, Ipamorelin stimulates GH release without significantly elevating cortisol, prolactin, or ACTH. This selectivity was demonstrated in early pharmacokinetic studies comparing equi-effective GH-releasing doses of Ipamorelin, GHRP-2, and GHRP-6.

Mechanism: Ipamorelin is a pentapeptide (Aib-His-D-2Nal-D-Phe-Lys-NH2) that binds to GHS-R1a with high specificity. It produces dose-dependent GH release with a ceiling effect — increasing the dose beyond a certain point does not produce proportionally more GH release, which provides a built-in safety margin against excessive GH elevation.

GH release profile: Onset within 15 to 20 minutes of subcutaneous injection. Peak GH levels at 30 to 45 minutes. Return to baseline within 2 to 3 hours. A typical 200 to 300 mcg dose produces GH peaks of 20 to 40 ng/mL in healthy adults (compared to a baseline of 0.5 to 3 ng/mL).

Side effects: Minimal. Transient injection-site reactions. Mild hunger increase in some users (less pronounced than GHRP-6). Water retention is possible but generally mild. No significant cortisol or prolactin elevation at standard doses.

Why it ranks first: The combination of meaningful GH release, minimal off-target hormonal effects, dose-dependent ceiling, and tolerability makes Ipamorelin the most broadly applicable GH secretagogue. It is the default choice for individuals who want GH optimization without significant side effect burden.

2. CJC-1295 (No DAC) / Modified GRF 1-29

Class: GHRH analog

Evidence level: Phase I/II human data

CJC-1295 without the Drug Affinity Complex (commonly called Mod GRF 1-29 or tetrasubstituted GRF 1-29) is a modified GHRH fragment with four amino acid substitutions that confer resistance to DPP-IV cleavage. This extends the half-life from 7 minutes (native GHRH) to approximately 30 minutes, allowing practical subcutaneous dosing.

Mechanism: Binds to GHRH receptors on pituitary somatotrophs. Amplifies GH pulse amplitude. Subject to somatostatin modulation, meaning it works best when dosed during natural GH release windows (before sleep, post-exercise).

GH release profile: Onset within 15 to 30 minutes. The amplification effect means that when combined with Ipamorelin or another GHRP, peak GH levels are substantially higher than either alone. When used as a standalone, the effect is more modest and depends on endogenous ghrelin tone.

Side effects: Facial flushing (vasodilatory effect, transient), mild headache in some users, injection-site irritation. No significant effects on cortisol, prolactin, or other hormones.

Why it ranks second: CJC-1295 (No DAC) is the ideal GHRH partner for Ipamorelin. The combination (typically 100 mcg CJC-1295 + 200-300 mcg Ipamorelin) is the most widely used GH peptide stack. As a standalone, it is less potent than a GHRP because it cannot overcome somatostatin inhibition.

Note on CJC-1295 with DAC: The DAC (Drug Affinity Complex) version binds to albumin, extending the half-life to 6 to 8 days. This produces a sustained GH elevation rather than discrete pulses, which more closely resembles exogenous GH administration than natural pulsatile release. For this reason, CJC-1295 with DAC is generally less preferred in protocols aiming to mimic physiological GH patterns, though it offers the convenience of less frequent dosing.

Tier 2: Effective with Caveats

3. Sermorelin

Class: GHRH analog

Evidence level: FDA-approved (previously), multiple clinical trials

Sermorelin is the full-length GHRH(1-29) analog, identical to the first 29 amino acids of human GHRH with the naturally occurring sequence. It was FDA-approved in 1997 for diagnostic evaluation of pituitary function and as a treatment for GH deficiency in children. The approval was later withdrawn for commercial reasons (not safety concerns), but Sermorelin remains available through compounding pharmacies.

Mechanism: Binds to GHRH receptors with the same affinity as native GHRH. The primary limitation is the short half-life (approximately 10 to 20 minutes), which requires injection timing close to natural GH release windows for optimal effect.

GH release profile: Rapid onset (10 to 15 minutes), relatively short duration of effect. Less potent per dose than CJC-1295 due to susceptibility to DPP-IV degradation.

Side effects: Facial flushing (common), injection-site pain, occasional headache. Generally well-tolerated. One advantage of Sermorelin is its extensive clinical safety data from its period of FDA approval.

Why it ranks third: Sermorelin has the best safety documentation of any GH secretagogue (clinical trial data, FDA approval history, long-term follow-up studies in children). However, it is less potent than CJC-1295 as a GHRH analog and has a shorter effective window. It is a solid choice for conservative protocols or individuals who prioritize the longest clinical safety track record.

4. GHRP-2

Class: GHRP (ghrelin receptor agonist)

Evidence level: Extensive human pharmacokinetic data, clinical studies

GHRP-2 (pralmorelin) is one of the most potent GH secretagogues by GH release magnitude. It produces substantially higher peak GH levels than Ipamorelin at equimolar doses. It was developed and clinically studied primarily in Japan, where it is approved as a diagnostic agent for GH deficiency (GHRP Kaken).

Mechanism: Potent GHS-R1a agonist with strong GH-releasing activity. Unlike Ipamorelin, GHRP-2 also stimulates ACTH and cortisol release (approximately 50 to 70% increase in cortisol) and modestly increases prolactin.

GH release profile: Onset within 10 to 15 minutes. Peak GH levels at 30 to 60 minutes. GHRP-2 consistently produces the highest GH spikes of any GHRP, making it attractive for users who prioritize maximal GH release.

Side effects: Cortisol elevation (potentially problematic for individuals with high baseline cortisol or adrenal issues). Prolactin elevation (mild, but relevant for individuals sensitive to prolactin-related side effects). Increased appetite (more pronounced than Ipamorelin, less than GHRP-6). Water retention.

Why it ranks fourth: Raw GH release potency is the highest in the GHRP class. However, the cortisol and prolactin effects are unwanted in most clinical contexts. For individuals specifically seeking maximal acute GH elevation and who are not cortisol-sensitive, GHRP-2 may outperform Ipamorelin on a per-dose basis. The trade-off in selectivity places it below Ipamorelin in overall ranking.

5. Tesamorelin

Class: GHRH analog

Evidence level: FDA-approved, RCTs

Tesamorelin (Egrifta) is a GHRH analog with a trans-3-hexenoic acid modification at the N-terminus that improves stability. It is FDA-approved for the treatment of HIV-associated lipodystrophy (excess abdominal/visceral fat). It is the only GH secretagogue with current FDA approval for any indication.

Mechanism: GHRH receptor agonist with improved stability over native GHRH. Produces physiological pulsatile GH release.

GH release profile: Well-characterized from RCTs. Produces clinically meaningful increases in GH and IGF-1. In the LIPO-010 and LIPO-011 pivotal trials, Tesamorelin reduced visceral adipose tissue by approximately 15% over 26 weeks.

Side effects: Injection-site reactions, arthralgia, peripheral edema, and myalgia are the most common. IGF-1 levels should be monitored and doses adjusted to keep IGF-1 within the age-appropriate normal range.

Why it ranks fifth: Tesamorelin has the strongest regulatory pedigree (FDA approval, RCT data, established safety monitoring) but is practically limited: it is expensive, requires a prescription specifically for HIV lipodystrophy, and off-label access is restricted compared to compounded peptides. For individuals who qualify, it is the most evidence-based option. For the broader population using GH secretagogues for anti-aging or performance purposes, the access barrier limits its applicability.

Tier 3: Effective but Higher Side Effect Burden

6. GHRP-6

Class: GHRP (ghrelin receptor agonist)

Evidence level: Extensive human pharmacokinetic data

GHRP-6 was one of the first synthetic GH secretagogues developed (1980s). It remains widely used and is the least selective of the common GHRPs: it produces strong GH release but with more pronounced effects on cortisol, prolactin, and especially appetite.

Mechanism: Potent GHS-R1a agonist. Unlike the other GHRPs, GHRP-6 produces a very strong ghrelin-like hunger signal. It also increases cortisol and prolactin to a similar or slightly greater degree than GHRP-2.

GH release profile: Comparable to GHRP-2 in magnitude. Onset within 10 to 15 minutes, peak at 30 to 60 minutes.

Side effects: Intense hunger within 20 to 30 minutes of injection (this is a feature for some users, such as those with poor appetite, but a significant side effect for those managing caloric intake). Cortisol elevation. Prolactin elevation. Water retention. Possible blood glucose effects due to cortisol-mediated insulin resistance.

Why it ranks sixth: GHRP-6 is the "dirtiest" of the common GHRPs in terms of off-target effects. The profound hunger stimulation limits its utility for body composition optimization. It still has a role in specific contexts: individuals who struggle to eat enough (elderly with sarcopenic malnutrition, individuals recovering from wasting conditions) may benefit from the appetite-stimulating properties. For general anti-aging or body composition use, cleaner alternatives exist.

7. Hexarelin

Class: GHRP (ghrelin receptor agonist)

Evidence level: Multiple human clinical studies

Hexarelin (examorelin) is the most potent GH secretagogue ever characterized in human studies. Single injections produce GH spikes exceeding 50 to 100 ng/mL in some subjects. However, this potency comes at a cost: Hexarelin produces the most pronounced cortisol and prolactin elevations of any GHRP, and — uniquely among GH secretagogues — shows significant tachyphylaxis (rapid loss of effectiveness) within 4 to 16 weeks of continuous use.

Mechanism: Extremely potent GHS-R1a agonist with additional binding to non-GHS-R receptors, which may explain its cardiovascular effects (Hexarelin has shown cardioprotective properties in preclinical models, mediated through a GHS-R-independent pathway involving CD36 receptors).

GH release profile: The highest acute GH release of any peptide in this class. However, GH response diminishes progressively with repeated dosing, even at the same dose. After 4 to 16 weeks of continuous use, GH response may be reduced by 50% or more.

Side effects: Significant cortisol elevation (higher than GHRP-2 or GHRP-6). Pronounced prolactin increase. Water retention. The tachyphylaxis issue is its most significant practical limitation.

Why it ranks seventh: Despite unmatched acute potency, the tachyphylaxis makes Hexarelin poorly suited for sustained protocols. Users must cycle it (typically 4 to 8 weeks on, 4 to 8 weeks off) to maintain responsiveness. The pronounced cortisol and prolactin effects further limit its appeal. Hexarelin is most interesting as a research tool and for potential cardioprotective applications rather than as a primary GH optimization peptide.

Tier 4: Oral Alternative

8. Ibutamoren (MK-677)

Class: Non-peptide GH secretagogue (ghrelin receptor agonist)

Evidence level: Multiple RCTs, extensive human data

Ibutamoren is technically not a peptide — it is a small-molecule spiropiperidine that acts as a potent, orally active ghrelin receptor agonist. It is included here because it competes directly with peptide GH secretagogues in practice and is frequently discussed alongside them.

Mechanism: Orally bioavailable GHS-R1a agonist. Produces dose-dependent, sustained GH elevation with a long duration of action (24-hour half-life). Unlike injectable GHRPs that produce discrete GH pulses, Ibutamoren produces sustained elevation in baseline GH and multiple amplified pulses.

GH/IGF-1 response: The most extensive RCT data of any GH secretagogue. At the standard 25 mg daily dose, Ibutamoren increases IGF-1 levels by approximately 40 to 90% and sustains this elevation for as long as dosing continues. In elderly populations, Ibutamoren restores GH and IGF-1 to young-adult levels.

Side effects: This is where Ibutamoren diverges from the clean-profile peptides. Significant appetite increase (ghrelin-mediated). Water retention and edema. Increased fasting blood glucose and decreased insulin sensitivity. Potential worsening of insulin resistance. Lethargy and drowsiness (particularly in the first few weeks). Muscle cramps. Numbness and tingling.

The insulin resistance issue is particularly important. In a 12-month RCT in elderly subjects, Ibutamoren produced clinically meaningful increases in fasting glucose and HbA1c. For individuals with pre-existing insulin resistance, metabolic syndrome, or type 2 diabetes risk, this side effect may outweigh the benefits of GH/IGF-1 elevation.

Why it ranks eighth: Ibutamoren's oral bioavailability is its defining advantage — no injections, simple daily dosing. However, the metabolic side effects (insulin resistance, glucose elevation), pronounced appetite increase, and sustained rather than pulsatile GH elevation pattern make it the least physiological option in this guide. For individuals who cannot or will not use injectable peptides, Ibutamoren is the primary alternative. For individuals who can use injectable peptides, cleaner options exist.

Dosing Frameworks

Standalone Protocols

Ipamorelin standalone: 200 to 300 mcg subcutaneous, 1 to 3 times daily (before bed is the highest-yield single dose due to synergy with sleep-related GH release). Continuous use is generally well-tolerated without tachyphylaxis.

Sermorelin standalone: 200 to 500 mcg subcutaneous before bed. Best timed 30 to 60 minutes before sleep to align with the natural nocturnal GH surge.

Ibutamoren standalone: 12.5 to 25 mg oral, once daily. Most users dose before bed to minimize appetite-related issues during the day and leverage sleep-related GH amplification.

Combination Protocols

CJC-1295/Ipamorelin: The standard stack. 100 mcg CJC-1295 (No DAC) + 200 to 300 mcg Ipamorelin, 1 to 3 times daily. This combination exploits the GHRH + GHRP synergy for maximal pulsatile GH release. The most common approach is once daily before bed, with more aggressive protocols adding a morning or post-workout dose.

GHRP-2 + CJC-1295: For users who want maximum GH release and are not concerned about cortisol elevation. 100 to 200 mcg GHRP-2 + 100 mcg CJC-1295 (No DAC). This produces higher peak GH than the Ipamorelin combination but with cortisol co-stimulation.

Timing Considerations

GH secretagogues are best administered on an empty stomach. Elevated blood glucose and free fatty acids blunt the GH response to GHRP and GHRH stimulation. A general rule: fast for at least 60 to 90 minutes before dosing and 30 to 60 minutes after dosing.

The three highest-yield dosing windows are:

1. Before bed (30 to 60 minutes pre-sleep) — synergizes with natural nocturnal GH pulse
2. Upon waking (fasted) — takes advantage of overnight fast and low somatostatin tone
3. Post-exercise (30 to 60 minutes after training) — leverages exercise-induced GH priming

Monitoring and Safety

Blood Work

All GH secretagogue protocols should include periodic monitoring:

IGF-1 levels: The primary marker. Target range is age-appropriate normal (typically 150 to 350 ng/mL for adults). Persistently elevated IGF-1 above the age-appropriate range increases theoretical risk for accelerated aging and neoplastic growth.

Fasting glucose and HbA1c: Particularly important with Ibutamoren, but relevant for all GH secretagogues since GH has anti-insulin effects.

Cortisol: Relevant if using GHRP-2, GHRP-6, or Hexarelin. A morning cortisol check provides baseline, though the peptide-induced cortisol elevation is transient.

Complete metabolic panel: Liver and kidney function, electrolytes.

When to Stop or Adjust

Discontinue or reduce dosing if:

• IGF-1 exceeds the upper limit of the age-appropriate reference range
• Fasting glucose increases beyond baseline by more than 10 to 15 mg/dL
• Persistent edema, carpal tunnel symptoms, or joint pain develop (signs of excessive GH effect)
• New or worsening insulin resistance is detected

Contraindications

GH secretagogues are contraindicated in:

• Active malignancy (GH/IGF-1 axis stimulation is theoretically pro-proliferative)
• Diabetic retinopathy (GH can worsen retinal neovascularization)
• Uncontrolled diabetes
• Pregnancy and breastfeeding
• Individuals under 25 (endocrine development is ongoing)

The Evidence Quality Problem

An honest assessment of the evidence landscape is necessary. The compounds in this guide span a wide range of evidence quality:

Strong evidence (clinical trials, FDA approval): Tesamorelin, Sermorelin, Ibutamoren

Moderate evidence (human pharmacokinetic/pharmacodynamic data, limited clinical studies): GHRP-2, GHRP-6, Hexarelin, Ipamorelin, CJC-1295

Limited evidence for long-term outcomes: All of them. No GH secretagogue has been studied in large, long-term RCTs powered for hard clinical outcomes (cardiovascular events, mortality, cancer incidence) in the general population. The longest-term data comes from Ibutamoren (2-year studies) and Tesamorelin (18-month studies in HIV populations).

The theoretical case for GH optimization is built on the observation that GH and IGF-1 decline with age (somatopause) and that this decline correlates with adverse body composition changes, reduced bone density, decreased skin thickness, impaired recovery, and reduced sleep quality. Whether reversing this decline with secretagogues produces net long-term benefit, net harm, or is neutral remains an open question. Animal data on GH/IGF-1 and longevity is conflicting — reduced GH/IGF-1 signaling extends lifespan in multiple model organisms, which complicates the "more GH is better" narrative.

Summary Table

Peptide	Class	Selectivity	Evidence	Key Advantage	Key Limitation
Ipamorelin	GHRP	High	Moderate	Clean side effect profile	Not the highest GH release
CJC-1295 (No DAC)	GHRH	High	Moderate	Best GHRH partner for stacking	Less effective as standalone
Sermorelin	GHRH	High	Strong	Best safety documentation	Short half-life, lower potency
GHRP-2	GHRP	Moderate	Moderate	Highest GHRP-class GH release	Cortisol/prolactin elevation
Tesamorelin	GHRH	High	Strong	FDA-approved, RCT data	Access restricted, expensive
GHRP-6	GHRP	Low	Moderate	Appetite stimulation (if desired)	Hunger, cortisol, prolactin
Hexarelin	GHRP	Low	Moderate	Highest acute GH release	Tachyphylaxis, cortisol
Ibutamoren	Non-peptide	Moderate	Strong	Oral dosing, long-acting	Insulin resistance, appetite

The optimal choice depends on individual goals, risk tolerance, and practical constraints. For most users seeking GH optimization with the best risk-to-benefit profile, the CJC-1295/Ipamorelin combination remains the standard of care in peptide therapy as of 2026.